The transaction provides Amgen with a late-stage phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on hemodialysis.
The deal was originally announced June 4.
The transaction provides Amgen with a late-stage phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on hemodialysis.
The deal was originally announced June 4.